Abstract
Despite therapeutic advances, lung cancer remains a leading cause of cancer death worldwide. Nectin-4, a cell adhesion molecule, is highly expressed in several epithelial tumor types, including non-small cell lung cancer (NSCLC). Targeting Nectin-4 in NSCLC provides a novel treatment approach. Enfortumab vedotin (EV) is an antibody-drug conjugate comprised of a fully human monoclonal antibody directed against Nectin-4, and monomethyl auristatin E (MMAE), a microtubule-disrupting agent, attached to the antibody via a protease-cleavable linker.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
